Skip to content
ppharmaranks
Menu

ponlimsi

Pharmaranks rates Ponlimsi 2.8/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Ponlimsi (Denosumab-Adet) is a medication supplied as an injectable.

Denosumab-Adet · by Teva

56/100Limited · 1 source

Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate
Verified againstopenFDANIH DailyMedRxClass

Key facts

Active ingredient
Denosumab-Adet
Form
Injectable
Strength
DENOSUMAB-ADET 60MG/ML
Type
Prescription (Rx)
Brand or generic
Brand-name
Manufacturer
Teva
FDA application
BLA761385

Dosage forms

Injectable

The forms currently marketed in the U.S., per the FDA National Drug Code Directory.

Ways to save

Ask for the generic

Same active ingredient, far cheaper. Is there a generic? →

Request a 90-day supply

Bulk fills usually lower the per-dose price vs monthly refills.

Use copay cards

Manufacturer copay cards & patient-assistance programs — especially for brand drugs.

Compare alternatives

A same-class option may cost less. See alternatives →

Frequently asked questions

How is Ponlimsi rated?
pharmaranks gives Ponlimsi a composite score of 2.8 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
Is there a coupon or discount for Ponlimsi?
pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Ponlimsi. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
Who makes Ponlimsi?
Ponlimsi is marketed by Teva. You can see Teva's full profile, rating, and other products on pharmaranks.
Is Ponlimsi a brand-name or generic drug?
Ponlimsi is a brand-name product with the active ingredient Denosumab-Adet.
Is Ponlimsi available over the counter?
No. Ponlimsi is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
What forms does Ponlimsi come in?
Ponlimsi is currently marketed as injectable, per the FDA's National Drug Code Directory.
Is Ponlimsi FDA-registered?
Ponlimsi is on record with the U.S. FDA under application number BLA761385. You can verify this on its official FDA label.
Has Ponlimsi been recalled by the FDA?
Ponlimsi has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
Is Ponlimsi safe?
There's no single safe-or-not verdict. pharmaranks gives Ponlimsi a recall-safety score of 56/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.

Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.

Reviews

No reviews yet. Be the first to write one.

Write a review

Reviews are user opinions, not medical advice. Consult a licensed professional.

People also viewed

Compare Ponlimsi head-to-head

Identify a pill by its imprint →Check a drug interaction →Drug recalls →

Browse medications A–Z

Research products from A to Z, compare independent ratings, and find alternatives.

ponlimsi

56/100